Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2. Detection of KIR4.1 autoantibodies using LIPS

Published byMaria Lattu Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2. Detection of KIR4.1 autoantibodies using LIPS"— Presentation transcript:

1 Figure 2. Detection of KIR4.1 autoantibodies using LIPS
Detection of KIR4.1 autoantibodies using LIPS (A) LIPS assay for KIR4.1 by rabbit antiserum for the KIR4.192–105 peptide. Anti-KIR4.1 antibodies bound KIR4.1-GL in a dose-dependent manner. The x-axis indicates the amount of antiserum for the KIR4.192–105 peptide. The y-axis indicates KIR4.1-GL activity. The lines with open and closed circles are the results using preimmune serum and antiserum for the KIR4.192–105 peptide, respectively. (B) LIPS assay for KIR4.1. Two patients with multiple sclerosis were positive for the anti-KIR4.1 antibody based on the LIPS assay (3.3%); none of the patients with NMO or NMOSD, or HCs, were autoantibody-positive. There were no statistical differences among the 3 groups (p = 0.469). The y-axis indicates the luciferase activity of KIR4.1-GL (in RLU). Red and black lines indicate the cutoff value and the mean values, respectively. GL = Gaussia luciferase; HC = healthy controls. KIR4.1 = inward rectifying potassium channel 4.1; LIPS = luciferase immunoprecipitation systems; NMO = neuromyelitis optica; NMOSD = NMO spectrum disorder; RLU = relative luminescence units. Osamu Higuchi et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e263 © 2016 American Academy of Neurology

Download ppt "Figure 2. Detection of KIR4.1 autoantibodies using LIPS"

Similar presentations

Figure 1. Absence of anti–neurofascin-155 (NF155) antibodies in combined central and peripheral demyelination (CCPD)‏ Absence of anti–neurofascin-155 (NF155)

Figure 1. Absence of anti–neurofascin-155 (NF155) antibodies in combined central and peripheral demyelination (CCPD)‏ Absence of anti–neurofascin-155 (NF155)
Figure 1 Stiff-person syndrome spectrum patient serum bound to membranes of live GlyRα1-transfected HEK293 cells Stiff-person syndrome spectrum patient.

Figure 1 Stiff-person syndrome spectrum patient serum bound to membranes of live GlyRα1-transfected HEK293 cells Stiff-person syndrome spectrum patient.
Figure 2 Orbital MRI findings One-third of myelin oligodendrocyte glycoprotein antibody–positive patients revealed extensive enhancement patterns that.

Figure 2 Orbital MRI findings One-third of myelin oligodendrocyte glycoprotein antibody–positive patients revealed extensive enhancement patterns that.
Figure 3 Antibodies to MOG using different secondary antibodies: Anti-human IgG (H + L), IgG1, or IgM(A) Comparison of binding to full-length myelin oligodendrocyte.

Figure 3 Antibodies to MOG using different secondary antibodies: Anti-human IgG (H + L), IgG1, or IgM(A) Comparison of binding to full-length myelin oligodendrocyte.
Figure 1 Percent positivity by clinical feature Overall, 6

Figure 1 Percent positivity by clinical feature Overall, 6
FL cells are dependent on BCL6 in a NOTCH2-dependent manner.

FL cells are dependent on BCL6 in a NOTCH2-dependent manner.
Figure 2 Expression of GABAA receptor and LGI1 by patient's thymomaTissue sections of the patient's thymoma incubated with biotinylated immunoglobulin.

Figure 2 Expression of GABAA receptor and LGI1 by patient's thymomaTissue sections of the patient's thymoma incubated with biotinylated immunoglobulin.
Figure 1 Reactivity of the patients' antibodies with rat brain and HEK cell-based assays Rat hippocampal dentate gyrus neuropils were stained with patient.

Figure 1 Reactivity of the patients' antibodies with rat brain and HEK cell-based assays Rat hippocampal dentate gyrus neuropils were stained with patient.
Figure 1 Flow diagram of the assays and the samples that were evaluatedA total of 1,109 samples were initially screened at a serum dilution of 1:20 for.

Figure 1 Flow diagram of the assays and the samples that were evaluatedA total of 1,109 samples were initially screened at a serum dilution of 1:20 for.
Figure 1 Neuromyelitis optica spectrum disorder (NMOSD) subgroups and patients with relapsing-remitting multiple sclerosis (RRMS) show different antibody.

Figure 1 Neuromyelitis optica spectrum disorder (NMOSD) subgroups and patients with relapsing-remitting multiple sclerosis (RRMS) show different antibody.
Figure 2 Elevated antibody reactivities against myelin and Epstein-Barr virus (EBV) peptides in relapsing-remitting multiple sclerosis (RRMS) and higher.

Figure 2 Elevated antibody reactivities against myelin and Epstein-Barr virus (EBV) peptides in relapsing-remitting multiple sclerosis (RRMS) and higher.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer

Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer
Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)
Figure 2 Binding of the patient's IgG to Purkinje cells is inhibited by pretreatment of rat tissue with anti-VGCC antibodies, confirming specificity of.

Figure 2 Binding of the patient's IgG to Purkinje cells is inhibited by pretreatment of rat tissue with anti-VGCC antibodies, confirming specificity of.
Figure 2 Mean serum concentrations of BIIB033 vs time(A) Single ascending dose study and (B) multiple ascending dose study. Mean serum concentrations of.

Figure 2 Mean serum concentrations of BIIB033 vs time(A) Single ascending dose study and (B) multiple ascending dose study. Mean serum concentrations of.
Figure 3 Effects of RTX on specific anti-pathogen IgGs

Figure 3 Effects of RTX on specific anti-pathogen IgGs
Figure 2. ROC curves for different group comparisons

Figure 2. ROC curves for different group comparisons
Figure 1 GABAB expression in the thymus(A–C) Staining of thymus tissue with anti-cytokeratin (A) and anti-GABAB antibody (B, C double immunofluorescence).

Figure 1 GABAB expression in the thymus(A–C) Staining of thymus tissue with anti-cytokeratin (A) and anti-GABAB antibody (B, C double immunofluorescence).
Figure 2 Concordance of results for commercial cell-based assay (CBA) and fluorescence-activated cell sorting (FACS) assays, FACS titers, and disease activity.

Figure 2 Concordance of results for commercial cell-based assay (CBA) and fluorescence-activated cell sorting (FACS) assays, FACS titers, and disease activity.

Similar presentations

Ads by Google